DDInter1340 DDInter364
Originally approved by the FDA in 1989, omeprazole is a _proton-pump inhibitor_, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approval was followed by the formulation of many other proton pump inhibitor drugs. Omeprazole is generally effective and well-tolerated, promoting its popular use in children and adults [FDA label].
Chlorpropamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Chlorpropamide is not recommended for the treatment of NIDDM as it increases blood pressure and the risk of retinopathy (UKPDS-33). Up to 80% of the single oral dose of chlorpropramide is metabolized, likely in the liver; 80-90% of the dose is excreted in urine as unchanged drug and metabolites. Renal and hepatic dysfunction may increase the risk of hypoglycemia.
Omeprazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Chlorpropamide
Omeprazole {u} (Compound) causes {v} (Side Effect) Pancytopenia
Pancytopenia {u} (Side Effect) is caused by {v} (Compound) Chlorpropamide
Omeprazole {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Probenecid
Probenecid {u} (Compound) resembles {v} (Compound) Chlorpropamide
Omeprazole {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Omeprazole {u} (Compound) causes {v} (Side Effect) Pancytopenia
Pancytopenia {u} (Side Effect) is caused by {v} (Compound) Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Omeprazole {u} (Compound) causes {v} (Side Effect) Pancytopenia
Pancytopenia {u} (Side Effect) is caused by {v} (Compound) Gliclazide
Gliclazide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Omeprazole {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is associated with {v} (Disease) type 2 diabetes mellitus
type 2 diabetes mellitus {u} (Disease) is treated by {v} (Compound) Chlorpropamide
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glimepiride
Glimepiride {u} (Compound) resembles {v} (Compound) Chlorpropamide
Omeprazole {u} (Compound) resembles {v} (Compound) Esomeprazole
Esomeprazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tolbutamide
Tolbutamide {u} (Compound) resembles {v} (Compound) Chlorpropamide
Omeprazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Chlorpropamide (Compound)
Omeprazole (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Chlorpropamide (Compound)
Omeprazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Probenecid (Compound) and Probenecid (Compound) resembles Chlorpropamide (Compound)
Omeprazole (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Gliclazide (Compound) and Gliclazide (Compound) resembles Chlorpropamide (Compound)
Omeprazole (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Glipizide (Compound) and Glipizide (Compound) resembles Chlorpropamide (Compound)
Omeprazole (Compound) causes Pancytopenia (Side Effect) and Pancytopenia (Side Effect) is caused by Gliclazide (Compound) and Gliclazide (Compound) resembles Chlorpropamide (Compound)
Omeprazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is associated with type 2 diabetes mellitus (Disease) and type 2 diabetes mellitus (Disease) is treated by Chlorpropamide (Compound)
Omeprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Glipizide and Glipizide (Compound) resembles Chlorpropamide (Compound)
Omeprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Glimepiride and Glimepiride (Compound) resembles Chlorpropamide (Compound)
Omeprazole (Compound) resembles Esomeprazole (Compound) and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Tolbutamide and Tolbutamide (Compound) resembles Chlorpropamide (Compound)